3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Urinary Bladder Neoplasms
2
Glioblastoma
2
Stomach Neoplasms
1
Solitary Pulmonary Nodule
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Pulmonary Nodules
1
Medication Adherence
1
Margins of Excision
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Early-stage Peripheral Non-small Cell Lung Cancer
1
Dementia
1
Cognitive Dysfunction
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Alzheimer Disease
1
Interventions
pembrolizumab
27
Oxaliplatin
24
Paclitaxel
22
Fluorouracil
21
Carboplatin
18
Leucovorin
16
Cisplatin
16
Capecitabine
16
Radiotherapy
15
Nivolumab
12
Drug Therapy
12
Radiation
10
Trastuzumab
9
Surgical Procedures, Operative
9
Immunotherapy
8
Magnetic Resonance Spectroscopy
7
Esophagectomy
7
Blood Specimen Collection
7
Taxes
6
durvalumab
5
Surveys and Questionnaires
5
Specimen Handling
5
Radiotherapy, Intensity-Modulated
5
Irinotecan
5
Immune Checkpoint Inhibitors
5
Docetaxel
5
Bevacizumab
5
tislelizumab
4
Ramucirumab
4
Fluorodeoxyglucose F18
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Drug Delivery Systems
×
1 year
×
Clear all
NCT05899985
2026-04-06
MAGMAP
Ferronova Pty Ltd
Phase NA
Active not recruiting
60 enrolled